JGC
KRYS icon

J. Goldman & Co’s Krystal Biotech KRYS Stock Holding History

J. Goldman & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,535
Closed -$378K – 781
2025
Q4 		$378K Buy
+1,535
New +$323K 0.01% 476
2024
Q2 		– Sell
-20,963
Closed -$3.73M – 529
2024
Q1 		$3.73M Buy
20,963
+15,555
+288% +$2.16M 0.12% 171
2023
Q4 		$671K Sell
5,408
-29,805
-85% -$3.31M 0.03% 256
2023
Q3 		$4.08M Buy
35,213
+29,864
+558% +$3.64M 0.14% 149
2023
Q2 		$628K Buy
5,349
+2,650
+98% +$271K 0.02% 279
2023
Q1 		$216K Sell
2,699
-16,620
-86% -$1.31M 0.01% 314
2022
Q4 		$1.53M Buy
19,319
+9,392
+95% +$697K 0.08% 192
2022
Q3 		$692K Sell
9,927
-4,063
-29% -$294K 0.03% 278
2022
Q2 		$919K Sell
13,990
-17,869
-56% -$1.11M 0.04% 253
2022
Q1 		$2.12M Buy
+31,859
New +$1.99M 0.1% 197
2021
Q4 		– Sell
-6,300
Closed -$329K – 396
2021
Q3 		$329K Sell
6,300
-4,651
-42% -$275K 0.02% 299
2021
Q2 		$745K Buy
10,951
+76
+0.7% +$5.3K 0.03% 300
2021
Q1 		$838K Sell
10,875
-5,543
-34% -$403K 0.03% 317
2020
Q4 		$985K Sell
16,418
-17,254
-51% -$862K 0.05% 236
2020
Q3 		$1.45M Sell
33,672
-11,530
-26% -$501K 0.1% 187
2020
Q2 		$1.87M Buy
+45,202
New +$2.17M 0.12% 167

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's KRYS Position: Q1 2026 in Review

J. Goldman & Co sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,535 shares — an estimated $378K sold.

J. Goldman & Co first reported a position in KRYS in Q2 2020 and held it in 16 quarters. The position peaked at $4.08M in Q3 2023. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • J. Goldman & Co reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 1,535 Krystal Biotech shares in Q1 2026, an estimated $378K.
  • J. Goldman & Co first reported a position in Krystal Biotech in Q2 2020 and held it in 16 quarters.
  • J. Goldman & Co's Krystal Biotech position peaked at $4.08M in Q3 2023.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.